Chemomab Therapeutics (CMMB) Net Income towards Common Stockholders (2017 - 2025)

Chemomab Therapeutics' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at $625.7 billion for Q4 2025.

• Quarterly Net Income towards Common Stockholders rose 65.9% year-over-year to $625.7 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $625.7 billion (up 65.9% YoY) and the FY2025 annual result came in at -$9.0 million, up 35.5% from the prior year.
• Net Income towards Common Stockholders was $625.7 billion for Q4 2025 at Chemomab Therapeutics, up from $1.7 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $625.7 billion in Q4 2025 and bottomed at -$5.1 million in Q1 2022.
• A 5-year average of $55.7 billion and a median of $3.7 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 199.53% — and 2024, when it jumped 11036839.42%.
• Chemomab Therapeutics' Net Income towards Common Stockholders stood at -$5.0 million in 2021, then jumped by 263.86% to $8.3 million in 2022, then slumped by 58.59% to $3.4 million in 2023, then soared by 11036839.42% to $377.1 billion in 2024, then surged by 65.9% to $625.7 billion in 2025.
• Business Quant data shows CMMB's Net Income towards Common Stockholders at $625.7 billion in Q4 2025, $1.7 million in Q3 2025, and $377.1 billion in Q4 2024.